In life sciences, three structures are emerging for AI-enabled research transactions — but each raises legal and strategic questions, requiring adaptations to existing deal frameworks…. By: Goodwin
Previous Story
5 Strategies to Strengthen Corporate Governance (UPDATED)
Next Story
Proprietary Data and Specialist AI: The Evolving Market in Life Sciences Transactions
